Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects

Authors

  • Jana D. Albrecht
  • Nadia Ninosu
  • Denise Barry
  • Thomas Albrecht
  • Marthe-Lisa Schaarschmidt
  • Sergij Goerdt
  • Jan P. Nicolay Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, DE-68167 Mannheim, Germany

DOI:

https://doi.org/10.2340/actadv.v102.2487

Keywords:

cutaneous T-cell lymphoma, pegylated interferon alfa-2a, interferon alfa-2a, drug-related side effects, vision disorder

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.

https://doi.org/10.1182/blood-2016-01-643569

Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.

https://doi.org/10.1182/blood-2006-10-054601

Dobos G, Pohrt A, Ram-Wolff C, Lebbe C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel) 2020; 12: 2921.

https://doi.org/10.3390/cancers12102921

Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med 2017; 37: 527-546.

https://doi.org/10.1016/j.cll.2017.06.006

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - Part 1: classification and diagnosis (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017; 15: 1266-1273.

https://doi.org/10.1111/ddg.13372

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - Part 2: treatment and follow-up (ICD10 C82 - C86). J Dtsch Dermatol Ges 2018; 16: 112-122.

https://doi.org/10.1111/ddg.13401

Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, et al. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2017; 31: 1841-1847.

https://doi.org/10.1111/jdv.14366

Husken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2012; 26: 71-78.

https://doi.org/10.1111/j.1468-3083.2011.04011.x

Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-551.

https://doi.org/10.2165/00003088-200140070-00005

Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23: 23-28.

https://doi.org/10.1055/s-2003-41631

Callizo J, Feltgen N, Pantenburg S, Wolf A, Neubauer AS, Jurklies B, et al. Cardiovascular risk factors in central retinal artery occlusion: results of a prospective and standardized medical examination. Ophthalmology 2015; 122: 1881-1888.

https://doi.org/10.1016/j.ophtha.2015.05.044

Rentiya ZS, Wells M, Bae J, Chen KJ, Chao AN, Turgeon N, et al. Interferon-alpha-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 2019; 257: 447-452.

https://doi.org/10.1007/s00417-018-04209-7

d'Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006; 44: 56-61.

https://doi.org/10.1016/j.jhep.2005.07.026

Kunkler AL, Binkley EM, Mantopoulos D, Hendershot AJ, Ohr MP, Kendra KL, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1771-1781.

https://doi.org/10.1007/s00417-019-04337-8

Downloads

Additional Files

Published

2022-05-24

How to Cite

Albrecht, J. D., Ninosu, N., Barry, D., Albrecht, T., Schaarschmidt, M.-L., Goerdt, S., & Nicolay, J. P. (2022). Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects. Acta Dermato-Venereologica, 102, adv00722. https://doi.org/10.2340/actadv.v102.2487